Parkinson's is often described as a movement disorder, yet anyone living with it knows it is far more than that. It reaches into sleep, mood, thinking, digestion and pain, and it changes not one part of the body but the balance of the whole.
At its centre is the slow loss of a particular group of brain cells, the dopamine producing neurons of a region called the substantia nigra. As these cells decline, the finely tuned circuits that plan and smooth our movements lose their conductor. Conventional treatment does a valuable job of replacing the missing dopamine, and for many years it can restore a great deal of normal life. Yet it works on one chemical in one pathway, while Parkinson's itself is a whole system drifting out of balance. The interest in supporting your endocannabinoid system is that it speaks to that wider picture, the inflammation, the oxidative stress, the disturbed sleep and mood, gently and from within. This guide explains, in plain terms, how that works and where the honest limits of the evidence lie.
What Parkinson's actually is
Deep in the brain sits a small cluster of cells that make dopamine, the chemical messenger that lets the body's movement circuits communicate smoothly. In Parkinson's, these cells are gradually lost. By the time the familiar signs appear, a large share of them has often already gone, which is why the condition tends to advance slowly and quietly for years before it is recognised.
Two processes drive much of that loss. One is neuroinflammation, a low, persistent activation of the brain's own immune cells that keeps the vulnerable neurons under stress. The other is oxidative stress, a build up of reactive molecules that the cell can no longer clear, damaging it from within. Alongside these, a protein called alpha synuclein begins to misfold and clump together, spreading from cell to cell and adding to the burden. The result is not a single fault but a self reinforcing cycle, in which inflammation, oxidative damage and protein aggregation feed one another.
Many symptoms from one root
This is why Parkinson's wears so many faces. The motor features, the tremor, the stiffness, the slowness and the trouble with balance, come from the failing dopamine circuits themselves. The non motor features, the broken sleep, the anxiety and low mood, the constipation, the pain and the changes in thinking, come from the same disease reaching into other systems, and they often begin years before any tremor. Understanding Parkinson's as one system out of balance, rather than a list of separate complaints, is the first step towards supporting it thoughtfully.
The body's master regulator
The endocannabinoid system, or ECS, is a signalling network that runs throughout your nervous system, your immune cells and your tissues. Its job is homeostasis, the constant fine tuning that keeps everything in balance. When something pushes the body out of its comfortable middle ground, whether that is stress, injury, inflammation or the slow strain of a neurodegenerative disease, the ECS is one of the systems that works to nudge it back.
It acts through two main receptors, known as CB1 and CB2, and through the body's own internal cannabinoids, called anandamide and 2-AG. Unlike many signalling molecules, these are not stored in advance. The body makes them on demand, exactly where and when they are needed, then breaks them down again once the job is done. This on demand quality is what makes the ECS such a precise local tool.
What makes it so relevant to Parkinson's is where it lives. CB1 receptors are among the most abundant of their kind in the brain, and they are especially dense in the very movement circuits that Parkinson's disrupts, the substantia nigra, the striatum and the globus pallidus. CB2 receptors sit largely on the immune cells that drive neuroinflammation. So the ECS is woven directly into both sides of the disease, the movement machinery and the inflammation that erodes it. Research also shows that this system does not stay unchanged as Parkinson's progresses. Its signalling shifts and adapts, which is part of why supporting it, rather than overriding it, is the approach we favour.
The movement dial
Densely expressed in the basal ganglia, the brain's movement hub. It helps regulate the balance of dopamine, glutamate and GABA that keeps movement smooth, which is why it is of such interest in both slowness and involuntary movement.
The inflammation switch
Found mainly on immune cells, quiet in healthy tissue but active once the brain's microglia are inflamed. Engaging it may calm that immune response around vulnerable neurons, without the intoxicating effects linked to CB1.
The balance channel
An ion channel found on dopamine neurons and involved in how pain is sensed. Compounds such as CBD engage it, and it is thought to play a part in fine tuning dopamine signalling and calming overactive pathways.
The slow dial
A switch inside the cell that turns down inflammation and supports the health of the cell's energy machinery over a longer timescale. CBD engages it, supporting a steadier anti-inflammatory and protective effect.
Mood, sleep and calm
A serotonin receptor that CBD activates. It is relevant to the anxiety, low mood and disturbed sleep that so often accompany Parkinson's, and may also bear on involuntary movement.
The net effect
Acting across these targets at once, the aim is the same as the ECS itself: to support the body's own efforts to protect its neurons, settle inflammation and steady the systems that Parkinson's unbalances.
Working within the movement circuits
The CB1 pathwayThe basal ganglia are the brain's movement control centre, a set of deep structures that decide which movements to release and which to hold back. Dopamine is the signal that keeps this system balanced. When it fades in Parkinson's, the circuit tips towards too little movement, producing the slowness and stiffness, while the long term use of dopamine replacement can tip it the other way, producing the involuntary movements known as dyskinesia.
CB1 receptors sit right inside these circuits, working alongside dopamine to shape the release of the other messengers, glutamate and GABA, that the system depends on. Because of this position, healthy CB1 signalling is thought to help buffer the circuit, smoothing the swings between too little and too much movement. This is the mechanistic reason for the longstanding interest in the ECS for both the slowness of Parkinson's and the dyskinesia that can complicate its treatment.
Why the system adapts as the disease moves
The ECS is not a fixed backdrop. As dopamine declines, the levels of the body's own cannabinoids and the number of CB1 receptors in the movement circuits change in response, part of the brain's attempt to compensate. This is why the goal of supporting the ECS is not to flood it or force it, but to back a system that is already trying to hold the line, and to do so steadily over time rather than in sudden pushes.
Settling the inflammation beneath it
The CB2 pathwayIf the CB1 story is about movement, the CB2 story is about protection. CB2 receptors live mainly on immune cells rather than neurons, and in healthy brain tissue they are largely quiet. In Parkinson's they become far more active, particularly on the microglia, the small resident immune cells of the brain. These microglia, meant to defend and repair, can shift into a persistently inflamed state that keeps the vulnerable dopamine neurons under attack.
Engaging CB2 is thought to encourage those immune cells to move from that inflamed, alarm raising state towards a calmer, resolving one. In laboratory terms this means fewer of the inflammatory messengers, such as the cytokines TNF-alpha, IL-1 and IL-6, that drive chronic neuroinflammation. Because CB2 sits away from the brain's CB1 receptors, this calming of inflammation comes without any intoxicating effect. In the animal models used to study Parkinson's, engaging the ECS in this way has been associated with a reduction in inflammation and greater survival of the dopamine producing neurons.
Oxidative stress and the antioxidant angle
Inflammation is only half of the internal picture. The other half is oxidative stress, the accumulation of reactive molecules that wear a neuron down. Several plant cannabinoids, and CBD in particular, act as direct antioxidants. In fact, in laboratory work CBD's antioxidant effect has been measured as stronger, molecule for molecule, than vitamins C and E. By mopping up some of this reactive burden and supporting the cell's own energy machinery, the aim is to ease one of the core stresses that pushes these fragile neurons towards decline.
The cannabinoids we build with
Cannabis and hemp contain not one active compound but many, and each engages the system in a slightly different way. Rather than relying on a single isolated molecule, we formulate with a considered range, so that the different compounds can work on different parts of the same problem, the movement circuits, the inflammation and the oxidative stress. Much of the detail below comes from laboratory and preclinical research, and is best read as the scientific rationale for the formulations rather than a promise of results.
The cornerstone. CBD reaches an unusually wide set of targets, the CB1 and CB2 receptors, TRPV1, PPAR gamma and the 5-HT1A serotonin receptor, and acts as a powerful antioxidant and anti-inflammatory. It also helps preserve the body's own anandamide by slowing the enzyme that breaks it down, supporting your natural endocannabinoid tone rather than replacing it.
Often called the mother cannabinoid, because the others are formed from it. In laboratory studies CBG has shown neuroprotective and antioxidant activity and an ability to calm inflammatory signalling, which is why it is of growing interest in neurodegenerative research.
These are the raw, unheated forms of CBD and CBG as they occur in the living plant. They engage the system differently from their heated counterparts and, in early research, show their own antioxidant and anti-inflammatory activity, which is why we value keeping some of the plant in its raw acidic state.
CBC has drawn attention for its possible role in supporting the health and viability of the brain's own progenitor cells, and for its anti-inflammatory activity. It is included as part of the wider supporting cast rather than as a lead compound.
CBN is best known for its gently calming, sleep supporting character, which is relevant given how disturbed sleep and REM sleep behaviour are for so many living with Parkinson's. It also shows antioxidant activity in laboratory settings.
A compound found naturally in black pepper and cloves that, unusually for a terpene, engages the CB2 receptor directly. This makes it a clean, non intoxicating way to support the inflammation calming side of the picture, complementing the cannabinoids it sits alongside.
A thoughtfully built formulation therefore tends to do more than any single isolated compound. The plant cannabinoids and the supporting terpenes work on different parts of the same problem, and they appear to complement one another when used together, an effect often described as the entourage of the whole plant.
The many faces of Parkinson's
Because Parkinson's reaches so widely, it helps to look at where ECS support is thought to fit across the whole spread of symptoms, motor and non motor alike. The two areas below are drawn from the mechanisms already described and from the early human research, and are offered as context rather than as claims of what any formulation will achieve.
The motor side
Tremor, rigidity and slowness. These arise directly from the failing dopamine circuits where CB1 receptors are so densely placed. The mechanistic interest is in helping to buffer and steady those circuits, and one small human study noted a reduction in tremor amplitude under stress after CBD.
Dyskinesia. The involuntary movements that can emerge from long term dopamine replacement are closely tied to the same circuits. The ECS has long been studied here, though the human results so far are mixed and far from settled.
Pain and stiffness. Much of the pain in Parkinson's is musculoskeletal and neuropathic, areas where ECS support has a clearer and longer track record.
The non motor side
Sleep and REM sleep behaviour. Disturbed, restless and acted out sleep is common and troubling. This is one of the areas where the early human evidence for cannabinoids has been most encouraging.
Anxiety and low mood. Through the 5-HT1A serotonin receptor and its wider calming action, CBD has shown a measurable reduction in anxiety in people with Parkinson's in small studies.
Quality of life and wellbeing. Where cannabinoids have helped most consistently, it has been in the broad sense of daily wellbeing and functioning, rather than in the core motor scores.
The pattern that runs through this is worth holding on to. The clearest signals so far have come from the non motor symptoms, the sleep, the mood and the overall sense of wellbeing, while the core motor features have been harder to shift. That shapes how we set expectations, and it is covered honestly further on.
Matching the formulation to the need
How a formulation is delivered matters as much as what is in it. Parkinson's is a deep seated, whole body condition, and in our approach the route that reaches it most completely is the one that should lead. For the deeper neurological, autoimmune and oncology support we are most often asked about, the suppository is the route we regard as the most powerful, with the sublingual and topical routes working alongside it rather than in its place. All three are formulated under Bonner Natural Health.
This is the route we build serious support around, and for a condition like Parkinson's we regard it as the most powerful of the three. A suppository is absorbed exceptionally well and largely bypasses the first pass through the liver, so a greater share of the formulation reaches the bloodstream, and it does so at steadier, more sustained levels than an oral route can hold. For a deep seated, whole body condition, that reliable systemic reach is exactly what is called for, which is why we take the same view for the neurological, autoimmune and oncology support we are so often asked about. It is also the most dependable option where swallowing is difficult, or where the digestive slowing of Parkinson's makes oral absorption unpredictable, both of which are common in the condition.
Taken under the tongue, a tincture is a valuable everyday companion to the suppository rather than a replacement for it. It enters the system quickly and allows for fine, adjustable daily dosing, useful for staying on top of mood, sleep and day to day steadiness between the deeper, sustained support the suppository provides.
Worked into stiff, aching muscles and joints, a topical adds focused, local relief on top of the systemic foundation. It acts on the cannabinoid receptors in the skin and on the local muscle and immune activity, which suits the rigidity, cramping and musculoskeletal pain that so often accompany Parkinson's, and it carries none of the whole body effects of the other routes.
Consistency tends to matter more than intensity. Because the approach works by supporting your own regulatory tone, it rewards steady daily use over a number of weeks rather than occasional high doses, and the suppository is the foundation we build that consistency on. The early human research points the same way, with the clearer benefits appearing over longer periods of use. Your practitioner can help tailor the routes, amounts and timing to your particular pattern of symptoms, and to the other medicines you take.
Where the science is strong, and where it is still growing
The mechanism explaining how ECS support could help in Parkinson's is well established and compelling. It rests on a large body of laboratory work, including the standard animal models of the disease, in which engaging the endocannabinoid system has reduced inflammation, lowered oxidative stress and helped protect the dopamine producing neurons. That is the strong part of the story, and it is the part this guide is built on.
The human evidence is more modest, and honesty here matters. In the clinical trials carried out so far, cannabinoids have not been shown to improve the core motor symptoms of Parkinson's, the tremor, slowness and stiffness measured on the standard rating scales. Where benefits have appeared, they have been on the non motor side. Small studies have reported improvements in wellbeing and daily functioning, in anxiety, in psychotic symptoms and in disturbed REM sleep, and a synthetic cannabinoid has been reported to help anxiety and sleep. The evidence on the involuntary movements of dyskinesia is genuinely mixed. Across the board these trials have been small and varied, which is why researchers agree that firmer conclusions await larger, better designed studies.
We therefore offer this as a sound, mechanism led way to support your body's own balance and to address some of the non motor burden of Parkinson's, always alongside proper clinical care and never in place of it. Cannabinoids can interact with other medicines, so it is important that anything you take is known to the clinician managing your Parkinson's, and that your existing treatment is never changed or stopped without their guidance. Any new or rapidly changing symptom, a fall, a sudden change in thinking or a swallowing difficulty, should always be reviewed by your medical team.
The person who formulated our protocols is Barry Bonner. Barry spent 25 years working in clinical medicine, in autoimmune disease, oncology, and pharmaceutical science, before suffering a stroke in 2017. In the years that followed, he undertook his own research into the ECS, the gut-brain axis, and the role of phytocannabinoids in neurological recovery.
What he discovered informed not just his own recovery, but the entire framework that became the Bonner Biotech protocol. This is not a business built from the outside in. It is built from lived experience, clinical knowledge, and a genuine conviction that the endocannabinoid system represents one of the most important and most underutilised tools available to anyone seeking to support their health from the inside out.
The ECS was always there. It was always working for you. We are here to help it work better.
Selected reading
A selection of the peer reviewed literature behind the mechanisms and early clinical findings described in this guide. These are scientific sources for the interested reader and do not constitute medical advice.
- Urmeneta-OrtÃz MF, et al. Potential neuroprotective effect of the endocannabinoid system on Parkinson's disease. Parkinson's Disease. 2024.
- Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology. 2020.
- Patricio F, et al. Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson's disease. Frontiers in Pharmacology. 2020.
- Zuardi AW, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology. 2009.
- Chagas MHN, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. Journal of Psychopharmacology. 2014.
- Chagas MHN, et al. Cannabidiol can improve complex sleep-related behaviours associated with REM sleep behaviour disorder in Parkinson's disease patients. Journal of Clinical Pharmacy and Therapeutics. 2014.
- de Faria SM, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. Journal of Psychopharmacology. 2020.
- Peball M, et al. Nabilone for non-motor symptoms of Parkinson's disease: the NMS-Nab randomised study. Journal of Neural Transmission. 2020.
- Sieradzan KA, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 2001.
- Urban DJ, et al. Randomised controlled trials on cannabis-based medicines in movement disorders: a systematic review. Journal of Neural Transmission. 2022.
- Aymerich MS, et al. Neuroprotective and disease-modifying effects of the endocannabinoid system in Parkinson's disease. Biochemical Pharmacology. 2018.